Screener
Catalyst Biosciences CBIO Q3 2026 earnings
Reported November 12, 2026 · After market close
Revenue$3.1MBeat by $2.5M
EPS-$0.90Miss by $0.20
Revenue estimate$625.0K
EPS estimate-$0.70
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027. We plan to aggressively pursue additional combination opportunities that can further our efforts to develop CR-001 as a best-in-class IO backbone therapy. Building on the pipeline progress we outlined last month, we are pleased to have now commenced patient dosing in the global APOLLO trial of CR-002, our PD-L1-targeted ADC. The team's strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types. We are poised for an exciting year ahead as we work to deliver the next wave of therapies for people living with cancer.”
Next report
Date not yet announcedVersus estimates
Revenue
Diluted EPS
FAQ
- When did Catalyst Biosciences report Q3 2026 earnings?
- Catalyst Biosciences (CBIO) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Catalyst Biosciences's Q3 2026 revenue and EPS?
- Catalyst Biosciences reported revenue of $3.1M and eps of $-0.90 for Q3 2026.
- Did Catalyst Biosciences beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $625.0K by $2.5M. EPS missed the consensus estimate of $-0.70 by $0.20.
- How did Catalyst Biosciences's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 29.1% from $-1.27.
- Where can I find Catalyst Biosciences's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-073409) and the 10-Q periodic report (0001628280-26-073389) directly on SEC EDGAR. The filing index links above go to sec.gov.
